Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
The Israel Medical Association Journal
To combat this, we are proud to offer B12 injections
You're injecting inactive compound
US$ 26.98
US$ 28.92
US$ 23.80
US$ 26.63
US$ 28.27
US$ 24.22
US$ 26.10
US$ 24.20
US$ 22.78
US$ 25.59
US$ 23.94
US$ 23.01
US$ 20.70
US$ 24.83
US$ 23.83
US$ 23.17
